In a National Bureau of Economic Research paper, Michael Kremer of Harvard and Christopher Snyder of Dartmouth explain why it is that drug companies, absent a nudge from a subsidy, favor research on drug treatments over research on vaccines.

FORBES: An Ounce of Prevention